Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

27 sept. 2021 07h00 HE | Source: Passage Bio

Passage Bio to Participate in Upcoming October Conferences

PHILADELPHIA, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for central nervous system (CNS)...
17 sept. 2021 16h01 HE | Source: Passage Bio

Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
07 sept. 2021 07h00 HE | Source: Passage Bio

Passage Bio Announces Maxine Gowen, Ph.D., as Chairwoman of the Board of Directors

PHILADELPHIA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
02 sept. 2021 07h00 HE | Source: Passage Bio

Passage Bio to Present at Citi 16th Annual BioPharma Virtual Conference

PHILADELPHIA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
27 août 2021 16h01 HE | Source: Passage Bio

Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
05 août 2021 07h00 HE | Source: Passage Bio

Passage Bio Reports Second Quarter 2021 Financial Results and Provides Recent Business Highlights

Expanded strategic collaboration with University of Pennsylvania’s Gene Therapy Program to advance genetic medicines for large CNS diseases, initially focused on Alzheimer’s Disease and Temporal Lobe...
04 août 2021 21h00 HE | Source: Passage Bio

Passage Bio Mourns the Sudden Passing of Chairman of the Board Tadataka Yamada, M.D.

PHILADELPHIA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
04 août 2021 07h00 HE | Source: Passage Bio

Passage Bio to Present at 12th Annual Wedbush PacGrow Healthcare Conference

PHILADELPHIA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic...
29 juil. 2021 07h00 HE | Source: Passage Bio

Passage Bio to Report Second Quarter 2021 Financial Results on August 5, 2021

PHILADELPHIA, July 29, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic...
21 juil. 2021 07h00 HE | Source: Passage Bio

Passage Bio Announces Inducement Award for Newly Appointed Chief Commercial Officer Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, July 21, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic...

Page précédente